Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tamoxifen (Primary)
- Indications Breast cancer
- Focus Pharmacogenomic; Pharmacokinetics
Most Recent Events
- 12 Mar 2021 Biomarkers information updated
- 18 Oct 2010 New trial record